Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

The first patient was dosed in the Phase 1 ZOLAR 7 trial of TLX300-CDx ( 89 Zr-olaratumab), which aims to validate the use of olaratumab, an antibody exclusively licensed from Eli Lilly and Company ...

Atopic dermatitis (AD ... Eli Lilly’s Olumiant is a first-in-class Janus kinase (JAK)1/2 inhibitor that was approved across ...

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...

With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers. The branded pharmaceutical industry relies on a high-cost, high-reward business model, driven by substantial investments in ...

The settlement in principle is with pharmaceutical company Mylan Inc. (Mylan) that will deliver up to $335 million nationwide to help combat the opioid crisis, according to Oregon Attorney General ...

A father and daughter remarkably transformed eight silos into an idyllic, multi-million pound family home - and it's just hit the market. Richard Dales, 58, and Olivia Ward, his 30-year-old ...

Eli Lilly and Co. is suing an Indianapolis-based ... It’s the latest in a slew of suits filed by the Indianapolis-based pharmaceutical company, which just last week announced it was suing ...

The biosimilar’s commercialisation and licence agreement between Biogen and Bio-Thera was established in April 2021, granting Biogen exclusive regulatory, manufacturing and commercial rights to ...

The Good Bug offers a natural probiotic-fiber blend for weight management, competing with pharmaceutical giants in the industry.

April 1 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ingredient in its popular ...